Figure 3.

VSV Immunotherapy Causes Tumor Infiltration by Inhibitory Receptor Expressing Effector T Cells

Mice were challenged with B16-OVA and treated with VSV-hgp100 as described in Figure 2. The tumors were harvested at day 22 post-challenge and analyzed by flow cytometry. (A) Tumor weight in grams of subcutaneous tumors harvested from mice at the time of sacrifice. (B and C) The fraction of live cells that were CD8⁺ or CD4⁺ in the tumor. (D and E) The number of CD8⁺ or CD4⁺ cells in 50 mg of tumor. (F and G) The fraction of CD8⁺ effector cells and the fraction of those effector cells double positive for expression of the inhibitory receptors PD-1 and TIM-3 (G). The median and interquartile range are shown. *p < 0.05.